celecoxib has been researched along with Acute Myelogenous Leukemia in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Solid lipid nanoparticles (CLX-SLN), nanostructured lipid carriers (CLX-NLC) and a nanoemulsion (CLX-NE) of celecoxib (CLX), a selective cyclooxygenase-2 inhibitor, were formulated for use in remedy of breast cancer and acute promyelocytic leukemia." | 7.91 | Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. ( Ergüven, M; Üner, M; Yener, G, 2019) |
| " Solid lipid nanoparticles (CLX-SLN), nanostructured lipid carriers (CLX-NLC) and a nanoemulsion (CLX-NE) of celecoxib (CLX), a selective cyclooxygenase-2 inhibitor, were formulated for use in remedy of breast cancer and acute promyelocytic leukemia." | 3.91 | Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia. ( Ergüven, M; Üner, M; Yener, G, 2019) |
| "Co-treatment with celecoxib and doxorubicin significantly inhibited cell growth and induced cell apoptosis in the acute leukemia cell line HL60 and primary AML cells." | 1.39 | Combination of celecoxib and doxorubicin increases growth inhibition and apoptosis in acute myeloid leukemia cells. ( Chen, C; Wang, CM; Xu, W, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Üner, M | 1 |
| Yener, G | 1 |
| Ergüven, M | 1 |
| Chen, C | 1 |
| Xu, W | 1 |
| Wang, CM | 1 |
| Du, LX | 1 |
| Jia, YQ | 1 |
| Meng, WT | 1 |
| Shi, FF | 1 |
| Zhong, XS | 1 |
| Ma, LL | 1 |
| Yuan, J | 1 |
| Zeng, JS | 1 |
| Casanova, I | 1 |
| Bosch, R | 1 |
| Lasa, A | 1 |
| Parreño, M | 1 |
| Céspedes, MV | 1 |
| Brunet, S | 1 |
| Nomdedéu, JF | 1 |
| Mangues, MA | 1 |
| Sierra, J | 1 |
| Mangues, R | 1 |
4 other studies available for celecoxib and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukemia.
Topics: Breast Neoplasms; Celecoxib; Colloids; Drug Carriers; Female; HL-60 Cells; Humans; Leukemia, Myeloid | 2019 |
Combination of celecoxib and doxorubicin increases growth inhibition and apoptosis in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cycli | 2013 |
[COX-2 inhibitor celecoxib can suppress the proliferation of FLT3-ITD positive acute myeloid leukemia cells with prominent down regulation of MEK/MCL-1 expression in vitro].
Topics: Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; fms-Like Tyrosine Kinase 3; G | 2013 |
A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 8; Celecoxib; Cell Adhesion; Cell Line, Tumor; Cyclooxygen | 2008 |